Clinical Trials Logo

VEGF Overexpression clinical trials

View clinical trials related to VEGF Overexpression.

Filter by:
  • None
  • Page 1

NCT ID: NCT04851054 Active, not recruiting - Surgery Clinical Trials

Postoperative VEGF and Recurrence After Colon Cancer Surgery

Start date: January 1, 2017
Phase:
Study type: Observational [Patient Registry]

The purpose of this trial is to study the relationship between the angiogenic response to surgical aggression, determined through the serum levels of vascular endothelial growth factor (VEGF) on postoperative day four, and the tumor recurrence in patients with colon cancer operated with a curative intention.

NCT ID: NCT03801044 Completed - Peritoneal Dialysis Clinical Trials

Lung Ultrasound in PD Patients

LUSiPD
Start date: May 1, 2018
Phase:
Study type: Observational

Although many alternative methods are present, maintaining ideal volume status in peritoneal dialysis (PD) patients still rely on clinical evaluation due to lack of an evidence based method. Lung ultrasound (LUS) is a new method for evaluation of hidden congestion in this group. LUS findings and its relationship with other volumetric methods are investigated in this study. LUS was performed to all peritoneal dialysis patients and compared with symptoms of hypervolemia, physical examination, vascular endothelial growth factor-C (VEGF-C) and N-terminal pro-brain natriuretic peptide levels, chest radiography, echocardiography, bioelectrical impedance analysis.

NCT ID: NCT03506750 Recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT)

CONCEPT
Start date: June 3, 2017
Phase: Phase 4
Study type: Interventional

Patients with proliferative diabetic retinopathy requiring surgical intervention will receive a pre-operative injection of Conbercept. Patients will be recruited into different groups according to variable time intervals (1 to 7 days) between intravitreous injection and surgery. At initial, pre-injection aqueous humor and blood sample will be collected in order to provide baseline VEGF-A, -B, placental growth factor (PIGF), and other cytokine levels. At the onset of the vitrectomy, a second aqueous humor, blood, and vitreous sample will be taken to obtain intra-operative levels of , VEGF-A, -B, PIGF, and other cytokine levels.